<p>CAR T-cell therapy has emerged as a revolutionary treatment for Non-Hodgkin's Lymphoma, particularly for patients with relapsed or refractory forms of the disease. This innovative approach involves modifying a patient&rsquo;s T cells to express chimeric antigen receptors (CARs) that target cancerous cells. The therapy has shown remarkable efficacy in patients with aggressive subtypes like Diffuse Large B-Cell Lymphoma (DLBCL) and has been approved by regulatory authorities such as the FDA. Despite its promising results, challenges remain, including the risk of severe side effects like cytokine release syndrome (CRS) and neurotoxicity, as well as the high cost of treatment. Ongoing clinical trials and advancements in CAR T-cell technology are expected to further refine its use, expand its applicability to other NHL subtypes, and enhance patient outcomes.</p>
<h2><strong>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Epidemiological Segmentation</strong></h2>
<ul>
<li>Total Incident Cases of Selected Indications for CAR-T in NHL (Mantle cell lymphoma, DLBCL, Follicular lymphoma, Marginal Zone Lymphoma, Primary mediastinal large B-cell lymphoma, Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma)</li>
<li>Total Indication wise Eligible Cases of CAR-T in NHL</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-nhl-epidemiology-forecast"><span style="text-decoration: underline;"><strong>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Epidemiology</strong></span></a></h2>
<ul>
<li>As per DelveInsight's estimates, in 2023, the total eligible cases of NHL for CAR-T therapy were around 126K in the 7MM.</li>
<li>DLBCL was the most prevalent subtype of non-Hodgkin lymphoma in the EU4 and the UK, with approximately 32K cases reported in 2023.</li>
<li>Japan recorded around 23,700 total NHL incident cases across selected subtypes in 2023.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market"><span style="text-decoration: underline;"><strong>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market</strong></span></a></h2>
<p>The CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size in the US was&nbsp; ~1,200 million in 2023.</p>
<h2>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Drivers:</h2>
<ul>
<li>Proven clinical efficacy in treating refractory and relapsed NHL.</li>
<li>Advancements in CAR T-cell technology and improved patient outcomes.</li>
<li>Increasing number of FDA-approved CAR T-cell therapies for NHL.</li>
<li>Growing market demand for personalized medicine and immunotherapies.</li>
</ul>
<h2>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Barriers:</h2>
<ul>
<li>High cost and complexity of CAR T-cell manufacturing and administration.</li>
<li>Limited availability of specialized centers for CAR T-cell therapy administration.</li>
<li>Risk of severe side effects, including cytokine release syndrome and neurotoxicity.</li>
<li>Regulatory and reimbursement challenges, delaying widespread adoption.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-pipeline-insight"><span style="text-decoration: underline;"><strong>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Emerging Drugs</strong></span></a></h2>
<ul>
<li>Cemacabtagene ansegedleucel</li>
<li>Rapcabtagene autoleucel</li>
<li>Zamtocabtagene autoleucel</li>
<li>AUTO4</li>
<li>CD30.CAR-T</li>
<li>PMB-CT01</li>
</ul>
<p>And others.&nbsp;</p>
<h2><strong>CAR T-Cell Therapy for Non-Hodgkin's lymphoma Key Players</strong></h2>
<ul>
<li>Allogene Therapeutics</li>
<li>Novartis</li>
<li>Miltenyi Biomedicine</li>
<li>Mustang Bio</li>
<li>Crispr Therapeutics</li>
<li>2seventy Bio</li>
<li>Imugene</li>
</ul>
<p>And others.</p>

CAR T for NHL Market Infographic

CAR T for NHL Symptions, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.